Shares of ACADIA Pharmaceuticals ACAD decreased in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share decreased 23.53% year over year to ($0.42), which beat the estimate of ($0.47).
Revenue of $121,007,000 up by 23.07% from the same period last year, which missed the estimate of $123,200,000.
Guidance
ACADIA Sees FY21 Net Sales For NUPLAZID $510M-$550M
Details Of The Call
Date: Feb 24, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/euu8bxfd
Price Action
52-week high: $58.72
Company's 52-week low was at $30.02
Price action over last quarter: Up 0.64%
Company Profile
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.